Abstract:Abstract Regulatory T cells (Tregs) maintain immune homeostasis by suppressing abnormal immune response to self and non-self-antigens. Tregs are also involved in tumor development and progression by inhibiting anti-tumor immunity. Infiltration of Tregs in the tumor microenvironment (TME) inhibit anti-tumor immunity by suppressing tumor antigen-specific T cell responses. This results in tumor progression and poor prognosis in patients with various types of cancers. Therefore, depletion of Tregs could be a promising immunotherapy target to augment the anti-tumor immune response. Molecules highly expressed by Tregs such as CD25, immune checkpoint molecules, and chemokine receptors have been targeted by antibodies or small molecules to deplete Tregs and its immunosuppressive function has been tested in the clinic. However, a thin line exists between augmenting effective immunity and inducing autoimmunity, posing difficulties in harnessing Tregs modulation in cancer treatment. Thus, additional strategies to selectively control Tregs are urgently needed for the effective treatment of cancer. In this study we evaluated the role of Tregs in suppressing the effector function of antigen-specific T cells and targeted killing of cancer cells in vitro. We observed Tregs mediated suppression of antigen-specific cytotoxicity against cancer cells. When Tregs were treated with cyclophosphamide, CD25 depleting antibody and anti-CTLA4 antibody alone or in combination, we observed enhanced killing of cancer cells in vitro as a result of potentiated effector function of antigen-specific T cells. This study provides a path forward to fine-tune and optimize strategies to target various molecules that are highly expressed on Tregs and augment anti-tumor immunity by antigen-specific T cells to achieve therapeutic outcome. Citation Format: Arif Azam Khan, Jaehyung Park, Nate LaVoy, Chris Tompkins, Jeff Bellinder, Tisha San Miguel, Neal Lawrence, Brianna Schoen. Reduction of immunosuppressive function of regulatory T cells enhances antigen-specific T cell mediated cytotoxicity against tumor cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 723.

The development and immunosuppressive functions of CD4+ CD25+ FoxP3+ regulatory T cells are under influence of the adenosine-A2A adenosine receptor pathway

TGF-β–Induced Regulatory T Cells Directly Suppress B Cell Responses Through a Noncytotoxic Mechanism

Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression

Impact of Regulatory T Cells on Innate Immune Cells in a Pre-Sensitized Heart Transplant Model

Adenosine Mediated Desensitization Of Camp Signaling Enhances T-Cell Responses

Adenosine Generated by Regulatory T Cells Induces CD8+ T Cell Exhaustion in Gastric Cancer Through A2aR Pathway.

Critical Roles of Adenosine A2A Receptor in Regulating the Balance of Treg/Th17 Cells in Allergic Asthma

A2A Adenosine Receptor Gene Deletion or Synthetic A2A Antagonist Liberate Tumor-Reactive CD8+ T Cells from Tumor-Induced Immunosuppression

Role of FoxP3+ regulatory T cells in modulating immune responses to AAV gene therapy

Adenosine production: a common path for mesenchymal stem-cell and regulatory T-cell-mediated immunosuppression

The Molecular Mechanisms of Regulatory T Cell Immunosuppression

IL-2 Can Signal Via Chemokine Receptors to Promote Regulatory T Cells' Suppressive Function.

Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine

Regulatory Activity of Activated Murine Peripheral Cd4(+)Cd25(-) T Cells: A Possible Mechanism of Feedback Regulation on Adaptive Immunity

Targeting immunosuppressive adenosine in cancer

Selective regulation of IFN-γ and IL-4 co-producing unconventional T cells by purinergic signalling

Targeting Hypoxia-A2A Adenosinergic Immunosuppression of Antitumor T Cells During Cancer Immunotherapy

Adenosine-A2A Receptor Pathway in Cancer Immunotherapy

Abstract 723: Reduction of immunosuppressive function of regulatory T cells enhances antigen-specific T cell mediated cytotoxicity against tumor cells

Enhancing the Antitumor Response of CD8+ T Cells by 4-1BB (CD137) Co-Stimulation with Distinct Inactivation of the Type 2 Adenosine Receptors

Immunosuppression of Human Adipose-Derived Stem Cells on T Cell Subsets via the Reduction of NF-kappaB Activation Mediated by PD-L1/PD-1 and Gal-9/TIM-3 Pathways.